Edition:
India

argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

227.86USD
1 Jul 2020
Change (% chg)

-- (--)
Prev Close
$227.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
58,897
52-wk High
$242.25
52-wk Low
$103.75

Summary

Name Age Since Current Position

Peter Verhaeghe

61 Non-Executive Independent Chairman of the Board

Tim Van Hauwermeiren

48 2014 Chief Executive Officer, Co-Founder, Executive Director

Werner Lanthaler

51 2014 Non-Executive Independent Vice Chairman of the Board

Eric Castaldi

55 2017 Chief Financial Officer

Keith Woods

52 2018 Chief Operating Officer

Hans de Haard

60 2008 Chief Scientific Officer

Arjen Lemmen

35 2019 Vice President - Corporate Development and Strategy

Dirk Beeusaert

56 2017 General Counsel

Wim Parys

60 2019 Chief Medical Officer

James Daly

58 2018 Non-Executive Independent Director

Joseph deBethizy

69 2015 Non-Executive Independent Director

Pamela Klein

58 2016 Non-Executive Independent Director

David Lacey

67 2014 Non-Executive Independent Director

Anthony Rosenberg

67 2017 Non-Executive Independent Director

Biographies

Name Description

Peter Verhaeghe

Mr. Peter K. M. Verhaeghe serves as Non-Executive Independent Chairman of the Board of the Company. He has served as a member and chairperson of the supervisory board of arGEN-X B.V. since October 2008 and as non-executive director on the Company's board of directors since July 2014. Mr. Verhaeghe is the managing partner of VVGB Advocaten—Avocats, a corporate finance law and tax law firm, a position he has held since July 1999. He is currently lead counsel to a number of Belgian, Dutch and Swiss biotechnology and diagnostics companies. Mr. Verhaeghe served as the president of the board of directors of Meri-sant France SAS, as a member of the management board of Merisant Company 2 sarl and serves as a member of the board of directors of CzechPak Manufacturing s. r. o. He previously served as the chairman of the board of directors of PharmaNeuroBoost NV from December 2006 to January 2013 and as liquidator in charge of KBC Private Equity Fund Biotech NV from April 2009 to December 2012. Mr. Verhaeghe holds a degree in law from Katholieke Universiteit Leuven, 1981, and an LLM degree from Harvard Law School of Harvard University, 1984. He is Member of the Audit Committee, and Member of the Remuneration and Nomination Committee of the Company.

Tim Van Hauwermeiren

Mr. Tim Van Hauwermeiren serves as Chief Executive Officer, Co-Founder, Executive Director of the Company. Tim Van Hauwermeiren co-founded the Company in 2008 and has served as its Chief Executive Officer since July 15, 2008. He has served as a member of the Company's board of directors since July 2014. Mr. Van Hauwermeiren has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors. Mr. Van Hauwermeiren holds a B. Sc. and M. Sc. in bioengineering from Universiteit Gent (Belgium) and an Executive MBA from the Vlerick Management School.

Werner Lanthaler

Dr. Werner Lanthaler Ph.D. serves as Non-Executive Independent Vice Chairman of the Board of the Company. Dr. Werner Lanthaler has served as a member of the Company's board of directors since July 2014. Dr. Lanthaler is the chief executive officer of Evotec AG, a global drug discovery research organization, a position he has held since March 2009. Dr. Lanthaler previously served on the supervisory boards of Bioxell SpA and Pantec Biosolutions AG. Dr. Lanthaler holds a degree in psychology from Universitaet Wien, a Ph. D. in business administration from Universitaet Wien of Economics and Business, and a Master’s degree in public administration from Harvard University. He is Chairman of the Audit Committee, and Member of the Remuneration and Nomination Committee of the Company.

Eric Castaldi

Mr. Eric Castaldi serves as Chief Financial Officer of the Company. Eric Castaldi has served as the Company's Chief Financial Officer since April 2014 and served as a member of the Company's board of directors from July 2014 to April 26, 2017. Mr. Castaldi has 29 years of international financial executive management experience, including 20 years in the biopharmaceutical industry. From 1998 to 2014, Mr. Castaldi served as chief financial officer and a member of the executive committee of Nicox SA, a Euronext-listed biotechnology company. From 2008 to 2012, he served as a member of the board of directors and as chairman of the audit committee of Hybrigenics SA, a Euronext-listed French biopharmaceutical company specializing in oncology. Mr. Castaldi graduated with a degree in finance, accountancy and administration from Universite de Nice in 1986.

Keith Woods

Mr. Keith Woods serves as Chief Operating Officer of the Company. Mr. Woods has over 25 years of experience in the biopharmaceutical industry. He most recently served as Senior Vice President of North American Operations for Alexion Pharmaceuticals Inc. (Alexion), where he managed a team of several hundred people in the U.S. and Canada and was responsible for more than $1 billion in annual sales. Within Alexion, he previously served as Vice President and Managing Director of Alexion UK, overseeing all aspects of Alexion’s U.K. business; Vice President of U.S. Operations; and Executive Director of Sales, leading the launch of Soliris in atypical hemolytic uremic syndrome. Prior to joining Alexion, he held various positions of increasing responsibility within Roche, Amgen and Eisai over a span of 20 years. Keith Woods holds a B.S. in Marketing from Florida State University.

Hans de Haard

Prof. Hans de Haard Ph.D. serves as Chief Scientific Officer of the Company. Prof. de Haard has been active in the antibody engineering field since 1989. He also serves as a Professor of Immunology at University of Franche Comte (France). Prof. de Haard holds an M. Sc. in biochemistry from the Higher Professional Education for Laboratory Technicians (Oss, the Netherlands) of Universiteit Maastricht, M. Sc. in chemistry from the Institute of Technology of Erasmus Universiteit Rotterdam (Rotterdam, the Netherlands) and a Ph. D. in molecular immunology from Universiteit Maastricht.

Arjen Lemmen

Mr. Arjen Lemmen serves as Vice President - Corporate Development and Strategy of the Company. He serves as the head of our strategy and corporate development activities. He joined argenx in 2016 and has successfully executed several transactions including a number of programs within our Innovative Access Program and our strategic collaboration with Janssen on cusatuzumab. Prior to joining argenx, he served as a corporate finance specialist at Kempen & Co focusing on M&A, Equity Capital Markets and strategic advi-sory transactions in the European life sciences industry. Mr. Lemmen holds a B.Sc. in Life Science & Tech-nology from the University of Groningen (the Netherlands) and Master of Engineering Management from Duke University. Arjen was promoted to Vice-President of Corporate Development & Strategy per June 1, 2019.

Dirk Beeusaert

Mr. Dirk Beeusaert serves as General Counsel of the Company. Mr. Beeusaert has extensive general experience in corporate governance and as general counsel of a listed company. Mr. Beeusaert worked in various roles from February 1996 to July 2016 for Gimv NV, a European private equity company listed on Euronext Brussels, including chief legal officer from January 2001 to 2006, and general counsel from 2006 to July 2016, where he was co-responsible for operations and corporate governance. Mr. Beeusaert currently serves as a member of the board of directors of Cubigo NV, and until November 2018 served as a member of the board of directors of Pragma Capital SAS. Mr. Beeusaert holds a Bachelor in Law and a Master Law degree from University of Ghent and an MBA in Fiscal Studies and Accounting Research, Tax and Accounting from Vlerick Business School.

Wim Parys

Mr. Wim Parys M.D. serves as Chief Medical Officer of the Company. As Development Head of Janssen’s Infectious Dis-eases and Vaccines therapeutic area, he lead the discovery and development of other medicines for HIV, Hepatitis C (Incivo™, Olysio™/Sovriad™), TB (Sirturo™) and respiratory viral diseases. In 2013 he became the R&D head of the newly established Global Public Health group, responsible for a portfolio including programs in HIV, TB, other mycobacterial infections, Dengue and Malaria. Wim joined argenx early 2019 as a development consultant and transitioned to the role of Chief Medical Officer on July 1, 2019.

James Daly

Mr. James Michael Daly serves as Non-Executive Independent Director of the Company. He holds a Bachelor in Science in Pharmacy and a Master in Business Administration from the State University of New York at Buffalo. He joined GlaxoSmithKline in 1985 where he held various positions, including Sr. Vice President – Respiratory Division with full responsibility for sales, marketing and medical affairs. He moved to Amgen in 2002 where he was Sr. Vice President for the North America Commercial Operations 2011. In 2012 he joined Incyte, a publicly traded company focused on oncology and inflammation, where he was chief commercial officer until June 2015. James Michael Daly currently serves as a director of Chimerix Inc, Acadia Pharmaceuticals, Coherus Biosciences, Halozyme Therapeutics and Bellicum Pharmaceuticals, all Nasdaq-listed companies.

Joseph deBethizy

Dr. Joseph Donald deBethizy Ph.D. serves as Non-Executive Independent Director of the Company. Dr. deBethizy has 30 years of experience in research and development and financial, business and operating management in the biotechnology and consumer products industry. He is the president of White City Consulting ApS. Previously, Dr. deBethizy served as president and chief executive officer of Santaris Pharma A/S until October 2014, when the company was sold to Roche. From August 2000 to June 2012, Dr. deBethizy was co-founder and chief executive officer of Targacept, Inc., a U.S. biotechnology company listed on Nasdaq. He currently serves on the supervisory boards of Albumedix A/S, Newron Pharmaceuticals SpA, Noxxon Pharma NV and AG, Rigontec GmbH and Proterris, Inc. From May 2013 to November 2014, he served as executive chairman of Contera Pharma ApS. He previously served on the boards of Asceneuron SA, Serendex Pharmaceuticals A/S, Enbiotix Inc., Targacept Inc. and Biosource Inc. Dr. deBethizy has held adjunct appointments at Wake Forest University Babcock School of Management, Wake Forest University School of Medicine and Duke University. Mr. deBethizy holds a B. Sc. in biology from the University of Maryland, and an M. Sc. and a Ph. D. in toxicology from Utah State University. He is Chairman of the Remuneration and Nomination Committee, and Member of the Research and Development Committee of the Company.

Pamela Klein

Dr. Pamela M. Klein serves as Non-Executive Independent Director of the Company. Dr. Klein is a principal and founder of PMK BioResearch, which offers strategic consulting in oncology drug development to corporate boards, management teams and the investment community, a position she has held since 2008. She currently serves as a member of various scientific advisor boards. Previously, Dr. Klein spent seven years at the National Cancer Institute as Research Director of the NCI-Navy Breast Center, after which she joined Genentech and was VP, Development until 2001. She served as Chief Medical Officer for Intellikine which was acquired by Takeda. She was previously Vice President, Development for Genentech. Dr. Klein holds a Bachelor’s degree in biology from California State University and an M. D. from Stritch School of Medicine, Loyola University, Chicago and is trained in internal medicine and medical oncology. She is Member of the Research and Development Committee of the Company.

David Lacey

Dr. David L. Lacey M.D. serves as Non-Executive Independent Director of the Company. Dr. Lacey is a bio-pharmaceutical consultant at David L. Lacey LLC, where he advises academic institutions, biotechnology companies and venture capital firms, a position he has held since July 2011. He currently serves as a director of Inbiomotion SL, Atreca, Inc. and Nurix, Inc. From 1994 until his retirement in 2011, he held various positions, including head of discovery research, at Amgen Inc., where he played a fundamental scientific role in the discovery of the OPG/RANKL/RANK pathway, which led to the development of the anti-RANKL human mAb denosumab, for both osteoporosis (Prolia) and cancer-related bone diseases (XGEVA). He holds a Bachelor’s degree in biology and an M. D. from the University of Colorado, and has his board certification in anatomic pathology. He is Chairman of the Research and Development Committee of the Company.

Anthony Rosenberg

Mr. Anthony A. Rosenberg serves as Non-Executive Independent Director of the Company. He currently serves as CEO of TR Advisory Services GmbH, a consultancy firm advising on business development, licensing and mergers and acquisitions. Mr. Rosenberg has also been a Managing Director of MPM Capital, a venture capital firm, since April 2015. From January 2013 until February 2015, he served as Corporate Head of M&A and Licensing at Novartis Pharma. He served as Global Head of Business Development and Licensing at Novartis Pharma from March 2005 to December 2012. Mr. A. A. Rosenberg holds non-executive board memberships Radius Health Inc., TriNetX, Inc., iOmx Therapeutics AG, Cullinan Oncology Inc. and Oculis SA. Mr. A. A. Rosenberg has a B.Sc. (Hons) from the University of Leicester and a M.Sc. Physiology from the University of London. He is Member of the Audit Committee of the Company.

Basic Compensation